Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Benzinga

Ultra-processed foods might not be the real villain in our diets – here’s what our research found

Ultra-processed foods (UPFs) have become public enemy number one in nutrition debates. From dementia to obesity and an epidemic of “food addiction”, these factory-made products, including crisps, ready meals, fizzy drinks and packaged snacks, are blamed for a wide range of modern health problems. Some experts argue that they’re “specifically…

The Conversation

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Benzinga

Wolverhampton cemetery’s extra fee for wider graves criticised as ‘fat tax’

Council says measure at Danescourt cemetery in Tettenhall is in response to increase in obesity levels in city

The Guardian - UK

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens

Vacations are on hold, dinners out skipped, and doses stretched — all so patients can keep taking weight-loss drugs like Wegovy and Zepbound as insurers pull back coverage in 2025.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The targeted programme found to improve IVF outcomes

Women who took part in a weight loss programme had a 21 per cent higher chance of becoming pregnant – whether naturally or through IVF

The Independent UK

Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud

As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, including Wegovy, Ozempic, and Mounjaro.

Fortune

Government partners with Mounjaro maker to tackle obesity

The £85 million programme will looks at ways for patients to access services more easily.

Evening Standard

Weight loss support before IVF could boost pregnancy chances – and reduce the need for treatment

Around one in five women of childbearing age are living with [obesity], defined by the World Health Organization as having a body mass index (BMI) over 30 kg/m². Compared with women in the healthy BMI range (18.5–24.9 kg/m²), those living with obesity are three times more likely to experience fertility…

The Conversation

Ozempic and other weight-loss drugs linked to rare but serious eye conditions

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

The Conversation

Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?

Shares of Novo Nordisk A/S (NYSE:NVO) climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly (NYSE:LLY)’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.

Benzinga

Portugal tightens rules on weight loss drug prescriptions to prevent misuse

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat type 2 diabetes and obesity but are also popular for weight loss.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Benzinga

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Evening Standard

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

The Independent UK

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The Conversation

Five things I wish everyone knew about weight loss – by an expert in nutrition

Weight loss continues to dominate public discourse – often framed as a matter of personal responsibility. But after nearly 15 years working in and around health and nutrition research, I’ve seen how weight is treated differently from almost every other health issue.

The Guardian - UK

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

Euronews

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Euronews

Obesity can be passed from parents to children. But do mothers’ or fathers’ genes matter more?

A new study suggests mothers’ genes could play an indirect role in shaping their children’s health, even when they aren’t passed on.

Evening Standard

OPINION - The real problem with Ozempic? The hell that comes after

It’s not actually that hard to imagine. Have you been on a diet? Have you ever lost weight? If so, the chances are you put that weight right back on again. I’ve done it. Oprah’s done it. Sam Smith have done it. My cat did it (RIP, my boy).

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

the University of Oxford

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.